ImmunityBio Inc. (NASDAQ: IBRX) lost 19% of its market value, falling to US$6.97, after third-quarter revenue missed analyst estimates and the company disclosed substantial doubt about its ability to continue as a going concern. The biotechnology company's positive clinical and regulatory news could not offset those two setbacks.

For the three months ended September 2026, ImmunityBio generated revenue of US$48.84 million — 52% growth year over year, but below the analyst consensus of US$59.25 million. The shortfall raised questions about whether demand is materializing as quickly as the market had expected. Revenue growth remains the key metric investors use to judge the commercial trajectory of the company's products.

How large was the loss?

Net loss attributable to shareholders widened to US$184.6 million, from US$67.3 million a year earlier. Diluted loss per share rose to US$0.18 from US$0.07.

The wider loss had two drivers:

• A US$77.9 million non-cash charge from changes in the fair value of a related-party convertible note (a debt instrument that can convert into shares), warrants and derivative liabilities — triggered partly by the rise in ImmunityBio's share price during the quarter;
• Higher research and development spending and selling expenses as the company advances its pipeline and commercializes its products.

The fair-value charge involved no actual cash outflow, but it distorts comparisons with prior periods. The research and selling increases, by contrast, reflect real spending.

What does the going-concern warning change?

The quarterly filing flagged substantial doubt about ImmunityBio's ability to continue as a going concern (a formal disclosure questioning whether a company can fund operations over the next twelve months) without additional funding. Management said it believes existing resources, future product sales, potential equity issuance and financial support from affiliated parties will be sufficient for at least 12 months.

That assessment rests on assumptions about future sales, capital-market access and affiliate support — none of them guaranteed. The numbers explain why the language matters: ImmunityBio held US$334.3 million in cash, cash equivalents and marketable securities at September 30, yet burned US$217.2 million in operating cash during the first nine months of the year. At that pace, the cash balance covers little more than a year.

The reference to potential equity issuance is the caveat embedded in management's reassurance. Issuing new shares dilutes existing shareholders, and the prospect of dilution likely sharpened the stock's decline.

Did the product news offer any counterweight?

ANKTIVA, ImmunityBio's bladder cancer treatment, generated net product revenue of US$48.7 million in the quarter, up 53% year over year. The company also reported that ANKTIVA combined with Bacillus Calmette-Guérin (BCG, an immunotherapy derived from a tuberculosis vaccine) met the primary endpoint in a late-stage trial of patients with previously untreated non-muscle-invasive bladder cancer.

Separately, Israel approved the combination for patients with BCG-unresponsive disease, bringing ANKTIVA's regulatory authorizations to 35 countries and widening its potential market.

Each promise carries a condition, however. Trial success does not guarantee approval, and a 35-country footprint does not guarantee revenue at the pace consensus expected — as this quarter's miss itself demonstrates.

What does this change for investors?

The 19% decline shows the market is weighing financing risk more heavily than product-level progress. The core tension is now between ANKTIVA's genuine momentum — growing revenue, a late-stage trial win, expanding approvals — and the company's immediate financial strain: a revenue miss, a wider loss and a going-concern warning.

Investors will watch three things in the coming quarters: ANKTIVA's revenue trajectory against consensus, the rate of cash burn relative to the US$334.3 million balance, and any announcement of funding or partnerships that would resolve the going-concern question. Until one of those moves, the contrast between operational progress and financial strain will remain central to how the market prices ImmunityBio.